Cargando…

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

Multiple myeloma (MM), the second most common hematologic malignancy, is characterized by the clonal expansion of plasma cells. Despite dramatic improvements in patients′ survival over the past decade due to advances in therapy exploiting novel molecular targets (immunomodulatory drugs, proteasome i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willenbacher, Wolfgang, Seeber, Andreas, Steiner, Normann, Willenbacher, Ella, Gatalica, Zoran, Swensen, Jeff, Kimbrough, Jeffery, Vranic, Semir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073692/ https://www.ncbi.nlm.nih.gov/pubmed/30021955 http://dx.doi.org/10.3390/ijms19072087

Ejemplares similares

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Targeting HER2 expression in cancer: New drugs and new indications
por: Vranić, Semir, et al.
Publicado: (2021)

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine
por: Gatalica, Zoran, et al.
Publicado: (2016)

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia
por: Willenbacher, Ella, et al.
Publicado: (2019)

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
por: Joneja, Upasana, et al.
Publicado: (2017)

Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
por: Topcagic, Jasmina, et al.
Publicado: (2018)

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast
por: Vranic, Semir, et al.
Publicado: (2018)

Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix
por: Cimic, Adela, et al.
Publicado: (2021)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016)

Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases
por: Skenderi, Faruk, et al.
Publicado: (2020)

Curcumin: New Insights into an Ancient Ingredient against Cancer
por: Willenbacher, Ella, et al.
Publicado: (2019)

Erratum: Willenbacher, E., et al. Curcumin: New Insights into an Ancient Ingredient against Cancer. Int. J. Mol. Sci. 2019, 20, 1808
por: Willenbacher, Ella, et al.
Publicado: (2020)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
por: Gargano, Stacey M., et al.
Publicado: (2019)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
por: Vranic, Semir, et al.
Publicado: (2022)

An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
por: Fojnica, Adnan, et al.
Publicado: (2023)

Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study
por: Lehmann, Jens, et al.
Publicado: (2023)

TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors
por: Kruslin, Bozo, et al.
Publicado: (2021)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
por: Zelle-Rieser, Claudia, et al.
Publicado: (2016)

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
por: Vukićević, Đurđa, et al.
Publicado: (2020)

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast
por: Vranic, Semir, et al.
Publicado: (2020)

NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
por: Luo, Wenyi, et al.
Publicado: (2021)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

Acinic cell carcinoma of the breast: A comprehensive review
por: Ajkunic, Azra, et al.
Publicado: (2022)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9es3rvekd5qkvkpa2j0kbefnqe